NORMAN, Oklahoma, Feb. 19 -- The University of Oklahoma issued the following news release: * * * Lancet Article Details Drug's Lack of Benefit for Head and Neck Cancer OKLAHOMA CITY, OKLA. - A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. Because cisplatin can damage the kidneys and cochlea, patients who have kidney problems or hearing  more